Ferritin in the antiphospholipid syndrome and its catastrophic variant (cAPS)

Agmon‐Levin, Nancy; Rosário, Cristina; Katz, B-S Porat; Zandman-Goddard, G; Meroni, Pier Luigi; Cervera, Ricard; Stojanovich, Ljudmila; Blank, Miri; Pierangeli, SS; Praprotnik, Sonja; Meis, Ernesto de; Seguro, Luciana Parente Costa; Ruffatti, Amelia; Pengo, Vittorio; Tincani, Anǵela; Doria, Andrea; Shoenfeld, Yehuda

doi:10.1177/0961203313504633

Cited by 62 publications

(46 citation statements)

References 63 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Such association was later confirmed in the largest multi-centre study to date published, that recruited 442 patients selected upon positivity for anti-β 2 GPI antibodies [44]. Later on, many other authors have conducted yet unpublished studies among aPL positive subjects, all concordantly confirming the relationship between anti-DI antibodies and thrombotic events affecting the venous as well as the arterial vascular tree [6,[45][46][47].…”

Section: Anti-domain I β 2 Glycoprotein I Antibodies In Apsmentioning

confidence: 84%

Reactivity against the Five Domains of β2 Glycoprotein I: A Focus on Systemic Lupus Erythematosus

Chighizola¹,

Borghi²,

Grossi³

et al. 2014

J Clin Cell Immunol

View full text Add to dashboard Cite

Beta-2 glycoprotein I (β 2 GPI) is the main antigenic target for antiphospholipid antibodies (aPL), the serological markers of antiphospholipid syndrome (APS), a systemic autoimmune disease characterized by vascular thrombosis and/or pregnancy morbidity. aPL are detected in 20 to 50% of patients with systemic lupus erythematosus (SLE), representing a poor prognostic factor. Indeed, thrombotic events heralds high morbidity and mortality, being regarded as the strongest predictors of death in the first five years after SLE onset. It would be thus very important to identify a reliable laboratory tool such as anti-domain antibodies to better risk-stratify lupus patients according to the aPL profile, in order to tailor treatment strategies. Domain I (DI) of β 2 GPI has lately been identified as the main epitope targeted by antibodies reacting against β 2 GPI isolated from APS patients, well correlating with thrombotic as well as obstetric manifestations. Interestingly, anti-DI antibodies have been shown to well correlate with lupus anticoagulant and to predict the clinical manifestations of the syndrome, thrombotic events as well as pregnancy complications. Further, anti-DI antibodies allow to identify patients at highest clinical risk, presenting a good specificity for APS. On the other hand, anti-β 2 GPI antibodies from aPL asymptomatic carriers or subjects with infectious diseases preferentially display reactivity towards DIV or DV of the molecule.Few studies have to date evaluated the domain profile of anti-β 2 GPI antibodies in subjects with SLE, even though it would be very relevant from a clinical point of view to understand whether among patients with SLE the domain specificities of anti-β 2 GPI antibodies display a clinical meaning comparable to the one they exert in APS. It is therefore rather appropriate to review the available evidence about anti-domain specificities with a particular focus on SLE.

show abstract

Section: Anti-domain I β 2 Glycoprotein I Antibodies In Apsmentioning

confidence: 84%

Reactivity against the Five Domains of β2 Glycoprotein I: A Focus on Systemic Lupus Erythematosus

Chighizola¹,

Borghi²,

Grossi³

et al. 2014

J Clin Cell Immunol

View full text Add to dashboard Cite

show abstract

“…Hyperferritinemia was reported to be correlated with the antiphospholipid syndrome, its catastrophic variant and the presence of anti-CMV antibodies among those patients. (61) Moreover, hyperferritinemia (≥1,250 µg/L) was reported to rule out some autoimmune diseases and hematologic diseases (62) where increased serum ferritin and reduced activity of iron-regulatory proteins were reported to indicate monocyte iron accumulation, which may be important for the pathophysiology of anemia of chronic diseases in humans. (63) Moreover, increased serum iron and ferritin constitute the hallmark of iron overload conditions as thalassemia, sideroblastic anemia and hemochromatosis.…”

Section: Therapeutic Importance Of Clearing Ferritin In Autoimmune DImentioning

confidence: 99%

Ameliorating Role Exerted by Al-Hijamah in Autoimmune Diseases : Effect on Serum Autoantibodies and Inflammatory Mediators

Baghdadi

Abdelaziz²,

Ahmed

et al. 2015

IJHS

View full text Add to dashboard Cite

Autoimmune diseases have common properties characterized by abnormal blood chemistry with high serum autoimmune antibodies, and inflammatory mediators. Those causative pathological substances (CPS) cannot be excreted by physiological mechanisms. Current treatments for autoimmune diseases involve steroids, cytotoxic drugs, plasmapheresis and monoclonal antibodies. Wet cupping therapy (WCT) of prophetic medicine is called Al-hijamah that treats numerous diseases having different etiology and pathogenesis via a pressure-dependent and size-dependent non-specific filtration then excretion of CPS causing clearance of blood and interstitial fluids. Al-hijamah clears blood passing through the fenestrated skin capillaries. Medical bases of Al-hijamah were reported in the evidence-based Taibah mechanism (Taibah theory). Al-hijamah was reported to be an excellent treatment for rheumatoid arthritis that improved patients' blood chemistry and induced significant clinical improvement and pharmacological potentiation. Al-hijamah improved the natural immunity and suppressed the pathological immunity through decreasing the serum level of autoantibodies, inflammatory mediators, and serum ferritin (a key player in autoimmunity). Al-hijamah reduced significantly pain severity, number of swollen joints and disease activity with no significant side effects. Main steps of Al-hijamah are skin suction (cupping), scarification (sharatmihjam in Arabic) and second suction (triple S technique) that is better therapeutically than the traditional WCT (double S technique). Whenever an excess noxious substance is to be removed from patients' blood and interstitial fluids, Al-hijamah is indicated.Shartatmihjam is a curative treatment in prophetic teachings according to the prophetic hadeeth: "Cure is in three: in shartatmihjam, oral honey and cauterization. I do not recommend my nation to cauterize".Al-hijamah may have better therapeutic benefits than plasmapheresis. Al-hijamah may be promising in treating autoimmune diseases as a sole treatment or adjuvant treatment.

show abstract

“…Гипер-ферритинемия при СКВ ассоциирована с серозитом, а также с тромбоцитопенией, высоким уровнем волчаноч-ного антикоагулянта и антикардиолипиновых антител и, таким образом, может служить одним из первых призна-ков вторичного антифосфолипидного синдрома (АФС) при СКВ [38,39]. Индексы активности СКВ значительно выше у пациентов с гиперферритинемией [39,40]. Наибо-лее высокие значения ферритина характерны для СКВ с катастрофическим АФС либо для вторичного САМ на фоне СКВ [40].…”

unclassified

“…Индексы активности СКВ значительно выше у пациентов с гиперферритинемией [39,40]. Наибо-лее высокие значения ферритина характерны для СКВ с катастрофическим АФС либо для вторичного САМ на фоне СКВ [40]. При анализе результатов клинико-лабора-торного обследования можно выявить наиболее сущест-венные различия при этих двух состояниях: при СКВ с ка-тастрофическим АФС характерно нарастание СОЭ, тогда как при вторичном САМ, наоборот, отмечаются резкое снижение этого показателя и нарастание СРБ [41].…”

unclassified

Juvenile-Onset Systemic Lupus Erythematosus: Clinical Features and Current Diagnostic Approaches

Каледа¹,

Nikishina²

2017

rsp

View full text Add to dashboard Cite

Ferritin in the antiphospholipid syndrome and its catastrophic variant (cAPS)

Cited by 62 publications

References 63 publications

Reactivity against the Five Domains of β2 Glycoprotein I: A Focus on Systemic Lupus Erythematosus

Reactivity against the Five Domains of β2 Glycoprotein I: A Focus on Systemic Lupus Erythematosus

Ameliorating Role Exerted by Al-Hijamah in Autoimmune Diseases : Effect on Serum Autoantibodies and Inflammatory Mediators

Juvenile-Onset Systemic Lupus Erythematosus: Clinical Features and Current Diagnostic Approaches

Contact Info

Product

Resources

About